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Abstract
Dupuytren’s disease is a fibroproliferative disease affecting the palmar fascia of the 
hand and leading to flexion contractures of the digits. It was first described in Northern 
European populations and derived its namesake from Dr. Baron Dupuytren, a French sur-
geon, who was one of the first to lecture on the disease. The etiology of Dupuytren’s dis-
ease is unclear but is likely influenced by both genetic and environmental factors. Older 
individuals and men are most at risk of developing the disease. Dupuytren’s disease is a 
clinical diagnosis and patients often present with gradually worsening flexion contrac-
tures. Mild disease is usually observed, but surgical treatment is preferred for debilitat-
ing contractures. A variety of surgical techniques have been described involving either 
incising or excising diseased fascia. Overall, surgery is effective in correcting contractures 
and improving function, but despite successful treatment some patients still experience 
recurrence. More recently, collagenase injections and percutaneous procedures have been 
utilized to treat Dupuytren’s disease and have yielded promising results in select patients.
Keywords: Dupuytren’s disease, collagenase, flexion contractures, palmar fascia, 
limited fasciectomy, percutaneous needle fasciotomy, fibroproliferative disease
1. Introduction
Dupuytren’s disease is one of the most common pathologies diagnosed in the field of hand 
surgery. It is a fibroproliferative disease of the palmar fascia characterized by flexion contrac-
tures of the digits and involves an abnormal production of type III collagen. The disease has 
a unique history with origins dating back to the Vikings and has been studied extensively 
since. However, despite ongoing research the etiology of the disease remains unclear but likely 
results from a complex interaction between genetics and environmental risk factors. Patients 
classically present with palpable palmar nodules and cords leading to gradual, progressive loss 
of function. The disease can potentially lead to debilitating flexion contractures of the digits 
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and affect activities of daily living. The disease is a clinical diagnosis and only requires further 
testing to exclude other pathologies. There is no cure for Dupuytren’s disease and treatment 
methods remain palliative. Patients with mild disease can be observed for disease progression 
while patients with more severe disease may be treated with a variety of procedures or surger-
ies. Recently, clinical procedures including collagenase injections and percutaneous needle fas-
ciotomy (PNF) have been utilized to successfully treat select patients. Still, surgery remains the 
preferred method of treating Dupuytren’s contractures for most surgeons. A variety of surgical 
techniques have been described utilizing different types of incisions to either incise or excise 
disease fascia and correct contractures. Surgery has yielded successful outcomes in regaining 
extension of the involved digits and improving function of the hand, however, it is not without 
risks. Complications related to infection, wound healing, and neurovascular injuries have been 
reported. In addition, despite successful treatment following surgery some patients experi-
ence recurrence of their contracture. Further research has focused on methods of successfully 
treating Dupuytren’s disease while reducing complications and recurrence. This chapter will 
provide a thorough description of Dupuytren disease from its history and pathophysiology to 
clinical management as well as highlight research related to patient outcomes.
2. History
Dupuytren’s disease is a condition of the hand with a unique history. Its origin is linked to the 
Viking population and likely spread throughout Northern Europe as the Vikings conquered 
and acquired lands in the ninth through thirteenth century. For this reason, it has since been 
given the colloquial name, “Viking disease.” The Viking’s 300-year conquest lead to many 
settlements in which their descendants lived and bred with native populations, leading to 
the spread of Dupuytren’s disease to many northern European nationalities [1, 2]. Naturally, 
as time progressed and more conquests occurred, the disease spread to the shores of North 
America, and is now found throughout the world.
Early evidence of diseases mimicking Dupuytren’s has been noted in historical texts. The “Curse 
of the MacCrimmons” is a tale of seventeenth century Scotland in which Clan MacCrimmons 
was cursed with a “bent finger,” leaving them unable to play their bagpipes [2, 3]. The Catholic 
Church sign of benediction has even been postulated to depict an early church priest with 
Dupuytren’s disease [2, 4]. Whaley and Elliot describe early Icelandic stories of the twelfth 
and thirteenth century possibly describing accounts of Dupuytren’s disease dating back to 
the ninth century and include the treatment of one case by a procedure resembling a palmar 
fasciotomy [5].
In 1831, the French surgeon and namesake to the disease Baron Guillaume Dupuytren gave a 
lecture on the “permanent retractions of the flexed fingers” [6]. Other surgeons have also been 
credited with describing conditions believed to be caused by Dupuytren’s disease, including: 
Felix Platter in 1680, Henry Cline, Jr. in 1808, and Sir Astley Cooper in 1818 [2]. Elliot dis-
cusses a “Cline’s contracture” as an earlier description of Dupuytren’s disease [7]. MacFarlane 
reports Platter may have been the first to publish a description of Dupuytren’s disease as early 
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as 1614 [2]. Despite possible earlier accounts, Dupuytren maintains the namesake of the dis-
ease to this day. Dupuytren finished his career as chief surgeon at the Hôtel de Dieu in Paris, 
and his name appears in at least 12 other diseases and instruments, cementing his legacy in 
the medical field [1].
Dupuytren’s disease is often considered a “disease of the north,” in to its northern European 
origins. Various studies into the prevalence of Dupuytren’s disease demonstrate its northern 
roots, showing Norway, Scotland, and Iceland with some of the highest prevalence when 
compared to more southern nations [8–10]. Today, Dupuytren’s disease can be seen in all 
types of patients; however, there are specific subsets of the population at in increased risk of 
developing the disease.
3. Epidemiology and risk factors
3.1. Prevalence
Dupuytren’s disease is most prominent in Northern European white males, especially greater 
than 40 years old. A study in the Netherlands reports a prevalence as high as 22% in the gen-
eral population [11]. The study also demonstrated a propensity for older populations with ages 
50–55 displaying a 4.9% prevalence, while those 76–80 years old having a prevalence of 52.6%. 
Men were also affected disproportionately more than women (26.4 vs. 18.6%). The prevalence 
in the US has been shown to approach 7.3% when including self-reported symptoms [12]. Other 
epidemiological studies show a male to female ratio in the US of 1.7:1 which approaches 1:1 
with increasing age [13]. Dupuytren’s disease has been linked to both genetic and environmental 
factors, both of which contribute to the prevalence in patient populations throughout the world.
3.2. Genetics
The genetic component of Dupuytren’s disease has been a topic of interest for many years. 
A study by Burge et al. found that the prevalence of Dupuytren’s in Norwegian individu-
als over 60 years old reaches 30%, indicating a familial component in like populations [14]. 
They also suggested an autosomal dominant inheritance pattern with variable penetrance 
based on pedigree analysis. Multiple heritable patterns have been hypothesized, but there 
is no clear consensus on a mode of transmission. It is possible the disease does not carry a 
simple inheritance pattern, but rather follows a more complex method similar to heart disease 
and diabetes. Ling et al. performed a study examining the family members of patients with 
Dupuytren’s disease, and found that 53% of men and 33% of women over the age of 60 in 
the family had signs of the disease [15]. In a clinical study, patients with a family history of 
Dupuytren’s disease had a 6-year earlier onset of disease compared to patients without a fam-
ily history [16]. There was also increased disease severity in terms of the number of affected 
digits and degree of contracture in patients with a family history. Both of these findings sug-
gest patients with a family history of Dupuytren’s disease develop a more severe and ear-
lier onset of disease. Research has also investigated specific genes linked to the development 
of Dupuytren’s, including the gene for TGF-β1. However, studies implicating TGF- β1 with 
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Dupuytren’s disease have been inconclusive [17]. The genetic predisposition of Dupuytren’s 
disease is complex and further research is needed to elicit a clear relationship between genet-
ics and disease manifestation.
3.3. Environmental factors
Despite Dupuytren’s genetic tendencies, multiple patients with no familial history of the dis-
ease are affected every year. Certain environmental factors have been associated with the devel-
opment of Dupuytren’s disease including smoking, alcohol use, diabetes, manual labor, and 
previous trauma. Hindocha et al. identified additional risk factors in developing Dupuytren’s 
and included frozen shoulder, epilepsy, and a high lipid profile [16]. There are many environ-
mental risk factors associated with Dupuytren’s disease; however, smoking, alcohol, diabetes 
mellitus, and previous trauma are the most well-established factors cited in current literature.
3.3.1. Smoking
There is a high prevalence of patients with Dupuytren’s disease who smoke cigarettes. A 
study found 76.5% of Dupuytren’s patients were smokers, while only 37.2% of the control 
group were smokers [18]. Another study examined 222 patients undergoing surgery to treat 
a Dupuytren’s contracture and found smoking was strongly associated with Dupuytren’s 
requiring surgical intervention (OR 2.8, 95% CI 1.5–5.2) [19]. The pathogenesis of Dupuytren’s 
disease from smoking is likely related to its impact on circulation. Cigarette smoking affects 
the small blood vessels causing microangiopathies, resulting in reduced blood flow to the dis-
tal extremities including the hands. The microvascular impairment from smoking is believed 
to contribute to the development of the Dupuytren’s disease. Smoking induced hypoxia 
of distal extremities leads to PDGF release, triggering endothelial and fibroblast activation 
resulting in increased collagen synthesis [8]. These vascular changes associated with smoking 
and collagen synthesis may contribute to the pathogenesis of Dupuytren’s. Overall, smoking 
is a modifiable risk factor that likely increases one’s risk of developing Dupuytren’s disease.
3.3.2. Alcohol
Though the role of alcohol is not clearly identified, it has been shown to be a risk factor for 
the development of Dupuytren’s disease. One study suggested alcoholic consumption leads 
to impaired liver function, and in turn altered palmar fat composition which could as a trigger 
for developing Dupuytren’s [20]. Heavy drinking was found to be more common in a study of 
Dupuytren’s patients awaiting surgery, and another study reported alcohol was the second most 
important risk factor after age in developing the disease [20, 21]. Additional studies suggest that 
alcoholics have a higher prevalence of Dupuytren’s disease compared to non-alcoholics (28 vs. 
22%, respectively) [22]. Though associations have been documented, further research is needed 
in identifying the role of alcohol as a modifiable risk factor for developing Dupuytren’s disease.
3.3.3. Diabetes mellitus
Multiple studies have identified a relationship between Dupuytren’s disease and diabetes, 
but there is no clear evidence its pathophysiology. Noble et al. reported a 42% incidence of 
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Dupuytren’s disease in adult diabetics and suggested Dupuytren’s severity is usually more 
mild and affecting the middle finger in diabetics [23]. In addition, 13% of 134 patients with 
Dupuytren’s disease were found to have elevated glucose levels, suggesting elevated blood 
glucose levels may influence development of Dupuytren’s disease. In another study, the pro-
portion of German diabetics with Dupuytren’s disease was only slightly higher than that of 
the normal population (11% compared to about 7%) [24]. Another study however, showed 
the prevalence of the disease in diabetic patients was as high as 32% [25]. Though the preva-
lence of DD in diabetics has been studied in various subpopulations, a consensus on the rela-
tionship between Dupuytren’s disease and diabetes mellitus has not been reached. Further 
research is needed to demonstrate a true mechanism of pathogenesis between Dupuytren’s 
disease and diabetes.
3.3.4. Trauma
Dupuytren himself first proposed previous trauma as a risk factor for developing the dis-
ease [26]. The progression of Dupuytren’s disease resembles normal physiologic healing and 
based on a patient’s risk factors, trauma may initiate a cascade of events leading to an aber-
rant healing response. It is unclear whether the development of disease is related to a single 
injury or rather multiple insults over time, but studies have reported the development of 
Dupuytren’s near the site of previous penetrating injuries [27]. Other studies have linked 
previous hand surgery such as carpal tunnel and trigger finger release to the development of 
Dupuytren’s disease [22, 25, 28, 29].
3.3.5. Other risk factors
The association between Dupuytren’s disease and epilepsy or anticonvulsants and has been 
reported. Lund et al. recorded a 50% prevalence of Dupuytren’s in male patients with epi-
lepsy and 25% in females [30]. Another study identified an overall prevalence of Dupuytren’s 
disease in 37% of epileptics [31]. Critchley et al. reported a 56% incidence of Dupuytren’s 
disease in chronic epileptic patients and an associated increased in disease with duration of 
epilepsy and possibly related to the administration of the anticonvulsant phenobarbital [32]. 
The effect of phenobarbital on DD was analyzed in a 2011 study, in which a dose-dependent 
fibrotic effect was seen with phenobarbital use. Though these studies demonstrate a relation-
ship between epilepsy and phenobarbital use in DD, other studies have found no direct cor-
relation to antiepileptic drugs [33, 34].
Manuel labor consisting of continued and repetitive hand use has also been proposed as a 
risk factor for developing Dupuytren’s disease. Lucas et al. reported the effect of personal 
and occupation exposures on the development of the disease and reported men who devel-
oped the disease had the highest exposure to biomechanical, vibration, and manual work [35]. 
After adjusting for personal risk factors, manual labor and the handling of vibratory tools 
had the strongest association with Dupuytren’s disease. Another study examining the effect 
of weekly hand transmitted vibration on the development of Dupuytren’s disease concluded 
the risk of developing Dupuytren’s contracture is more than double in men with increasing 
amounts of hand-transmitted vibration [34]. In addition, handwork for at least 30 years has 
also been reported as a possible risk factor in the development of Dupuytren’s disease [35].
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4. Anatomy and pathophysiology
4.1. Anatomy
A thorough understanding of anatomy is crucial to understanding Dupuytren’s disease and 
its progression. Dupuytren’s disease is a fibroproliferative disorder affecting the palmar apo-
neurosis, one of the three zones within the palmar fascial complex. The subcutaneous palmar 
aponeurosis is a continuation of the palmaris longus tendon, extending superficially to the 
palmaris brevis muscle and into the palmar surface. The palmar aponeurosis can be divided 
into three layers according to orientation: longitudinal, vertical, and transverse. The longi-
tudinal fibers extend to the phalanges where they bifurcate and terminate as three separate 
insertions. The superficial layer inserts into the dermis and the deep layer inserts into the 
flexor and extensor mechanisms. The middle layer of the longitudinal fibers travel vertically 
next to the metacarpophalangeal (MCP) joint capsule forming spiral bands. Vertical fibers of 
the palmar aponeurosis include the superficial Grapow fibers, which anchor the skin to the 
aponeurosis, and the septa of Legueu and Juvara, which create fibro-osseous compartments 
to allow passage of flexor tendons, neurovascular bundles, and lumbrical muscles. Transverse 
fibers of the palmar aponeurosis include the transverse ligament and the natatory ligament.
Dupuytren’s disease is characterized by the transformation of normal, palmar fascial bands 
into fibrotic, contracted tissue called cords. Different manifestations and stages of the disease 
are dependent on the anatomical bands that are affected. Early disease often affects the super-
ficial Grapow fibers, forming thickened skin in the affected area. Pretendinous cords are the 
most common and result in skin dimpling and MCP contracture. The spiral cord consists of 
the middle pretendinous band, spiral band, lateral digital sheet, and Grayson ligament result 
in MCP and proximal interphalangeal (PIP) contracture and can also be accompanied with a 
medially displaced neurovascular bundle [36]. Other cords that can form include the central 
and lateral cords which can lead to a combination of PIP or distal inter-phalangeal (DIP) con-
tractures while natatory cords can lead to web space contractures.
4.2. Pathophysiology
The pathophysiology of Dupuytren’s is similar to the normal connective tissue healing pro-
cess. However, there are aspects of the Dupuytren’s process that differ and contribute to its 
pathogenesis. In Dupuytren’s there is an increased number of myofibroblasts producing type 
3 collagen, a change in biochemical composition of the fascia, as well as an abundance of cyto-
kines and prostaglandins contribute to the pathogenesis. An immune mediated component of 
the disease has also been proposed and researched. Luck et al. describes three distinct micro-
scopic phases of Dupuytren’s disease [37]. The first stage is called the proliferative phase, and 
is characterized by increased fibroblast presence and proliferation in fascial bands, forming 
a nodule. On a cellular level, these nodules represent the accumulation of myofibroblasts, 
collagen, and extracellular matrix components within the palmar fascia, resulting in fibrotic, 
adherent lesions that decrease mobility of the joint. In this stage, there can be as high as a 
fortyfold increase in the amount of proliferating fibroblasts [38]. The active or “involutional” 
phase is dominated by myofibroblasts, which contain myofibrillar bundles in the cytoplasm, 
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allowing them to contract and draw tissue together. These muscle-like fibers align in the direc-
tion of stress [38, 39]. The residual phase is characterized by the disappearance of a nodule, 
and appearance of cords. The acellular cord causes shortening of the metacarpophalangeal 
(MCP) and proximal interphalangeal (PIP) joint and producing the classic contracted appear-
ance of Dupuytren’s disease. In the late phase, there is commonly impaired range of motion 
of the effected digit, and nerve damage and vascular insufficiency can occasionally be seen.
4.2.1. Myofibroblasts
Myofibroblasts are contractile cells that are α-smooth muscle actin positive and contribute to 
the contracture present in Dupuytren’s disease. During the early phase of disease, myofibro-
blasts become densely packed in the palmar aponeurosis and produce an increased type 
3/type 1 collagen ratio. The accumulation of fibroblasts and type III collagen creates the charac-
teristic early nodule. This abundant type 3 collagen production is similar to connective tissue 
scar formation, and may or may not contribute to the pathophysiology of Dupuytren’s disease 
[40]. The source of myofibroblasts in Dupuytren’s disease remains unclear. Some argue that 
the fibroblast-myofibroblasts transformation is induced by local ischemia and hypoxia.
4.2.2. Biochemical changes
Biochemical changes to the palmar fascia may contribute to the development of Dupuytren’s 
disease. These changes include increased glycosaminoglycan content, increased hydroxyly-
sine content, and increased reducible crosslinks found in affected palmar aponeuroses [40]. 
Myofibroblasts found in the palmar fascia produce fibronectin, a glycoprotein thought to 
encourage cell-cell and cell-extracellular matrix adherence [41, 42]. This contributes to the 
thickening of the palmar fascia seen in the disease. Dermatan sulfate has been found to be 
two fold greater in tissue affecting by Dupuytren’s and is known to affect collagen organiza-
tion, deposition rate, and maintenance of fibers [43]. The same study also demonstrated an 
increased heparin sulfate composition in patients with Dupuytren’s, which has been shown to 
play a role in cell recognition, adhesion, growth control, and angiogenesis. Research has also 
shown a change in the architecture of the palmar fascia in Dupuytren’s patients. Compared to 
normal fascia, fascia in Dupuytren’s patients has more hydroxyl-lysino-hydroxy-norleucine 
crosslinking which was absent in normal tissue [44, 45]. It is unclear how this increased cross-
linking component contributes to the severity of disease.
4.2.3. Cytokines and prostaglandins
Many studies have pointed to the role of growth factors and cytokines in the pathogenesis of 
Dupuytren’s disease. An increased production of IL-1α and IL-1β is seen in Dupuytren’s palmar 
fascia. These cytokines are involved in proinflammatory processes including local fibroblast 
proliferation, which can potentially contribute to the active stage of Dupuytren’s disease [46]. 
There is also an increase in bFGF which contributes to fibroblast growth and proliferation, 
and increased TGF-β, which contributes to collagen synthesis and fibroblast chemotaxis [46]. 
The study concluded that increased release of cytokines and growth factors relative to nor-
mal reparative tissue may suggest a locally driven fibroblast proliferation contributing to the 
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development of Dupuytren’s disease. Research has also demonstrated prostaglandins PGE2 
and PGF2α play a role in contractility of smooth muscle associated with myofibroblasts [44, 47]. 
This contractile influence on myofibroblasts is thought to contribute to the contraction of tis-
sue late in the disease. The source of these prostaglandins are possibly from microcirculation 
and perinodular fat, as nodules are highly vascularized and fatty.
4.2.4. Immune mediated
Studies have suggested an immune mediated response in the pathophysiology of Dupuytren’s 
disease. Mayerl et al. describe abundant accumulation of immune cells in Dupuytren’s tissue, 
including mononuclear CD3+, CD4+ > CD8+, and primarily a Th1 mediated response [39]. 
These clusters of immune cells were found around blood vessels in the area, suggesting the 
fibroproliferation exists in Dupuytren’s may be due to microvascular damage mediated by the 
immune system. Further research is required to determine the relationship of Dupuytren’s to 
an immune mediated response.
5. Clinical presentation and physical exam
A thorough history and physical exam is necessary to accurately diagnose Dupuytren’s dis-
ease, which has a classic presentation. It is important to assess risk factors including family 
history, northern European descent, smoking, alcohol use, history of diabetes mellitus, or pre-
vious trauma to the hand in order to gain a broader picture of the patients’ presentation. In 
many cases, disease is bilateral with one hand affected more than the other so it important to 
evaluate both hand. The ring finger is the most commonly affected digit followed by the small, 
middle, index, and thumb [48]. Other fibroproliferative diseases have been associated with 
Dupuytren’s disease and include Garrod’s nodes, Ledderhose disease, and Peyronie’s disease. 
Garrod’s nodes, also called knuckle pads, can be visualized on the dorsal PIP joints and are 
subcutaneous nodules that histologically portray myofibroblasts proliferation. Ledderhose is 
a fibrosis of the plantar fascia and Peyronie’s disease is an inflammation and scarring of the 
tunica albuginea of the penis. Rayan et al. described three phases to Dupuytren’s disease clini-
cal presentation: the early, intermediate, and late phases [49]. These three phases provide a 
good framework to assess the patient’s disease status, and each phase is characterized by 
distinct aspects of the disease.
5.1. Early phase
Early disease is characterized by skin dimpling, puckering, and pitting, usually on the medial 
aspect of the palm. These changes can lead to the patient seeking medical attention, however 
are also easily ignored by some patients. A Dupuytren’s patient population study suggests that 
approximately 11% of Dupuytren’s disease patients seek attention from their physician with a 
chief complaint of skin changes on the palm [12]. Physical exam during the early phase of dis-
ease can confirm these skin changes upon inspection. Pitting of skin on the medial palm of the 
hand is a good indication of developing Dupuytren’s disease. Palpation reveals thickening and 
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dimpling of the skin around the effected joint. The underlying fat on the medial palm becomes 
fibrotic near the distal palmar crease. Active range of motion (ROM) and strength testing in 
early disease will reveal no limitations, though more severe skin adhesions can lead to a slight 
decrease in mobility and function of the affected digits in some patients.
5.2. Intermediate phase
The appearance of Dupuytren’s nodules and cords signifies the intermediate phase of disease. 
Nodule formation is often one of the first patient complaints and occurs during intermediate 
stages of the disease. Approximately 42% of patients with Dupuytren’s disease present to the 
office due to a nodule [12]. Nodules most commonly form proximal to the palmar crease over-
lying the metacarpophalangeal joint of the affected digit, and encompass the superficial layers 
of the palmar and digital fascia. Sometimes digital nodules are seen at the base of the proximal 
interphalangeal joint. Though often painless, larger nodules can cause pain when they exert 
pressure on underlying flexor tendons. Painful, chronic nodules are more indicative of intrinsic 
joint disease and rheumatoid arthritis, and must be differentiated from a Dupuytren’s disease 
nodule. After the appearance of a nodule, a pathologic cord may form within the palmar fas-
cia. Approximately 12% of patients seek will seek care following development of a cord [12]. 
Nodules often regresses, but in some cases can be present simultaneously with Dupuytren’s 
cords. Initial cords are often unnoticeable and blend in with the underlying connective tis-
sue, but over time, they become thick and resemble subcutaneous tendon-like structures 
upon inspection (Figure 1). Palpation reveals an immobile, thickened cord. Cord formation is 
extremely variable in terms of location. The most common cords arise in the palm, and include 
peritendinous, natatory, and vertical cords arising from their respective bands in the palmar 
Figure 1. A patient with Dupuytren’s cords leading to contractures and affecting the bilateral small and ring fingers.
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Tubiana stage Degrees of extension deficit
0 0, No disease
N 0, Nodules present
I 1–45
II 46–90
III 91–135
IV >136
Table 1. Tubiana staging system based on a digit’s total extension deficit [51, 52].
fascia. Digital cords frequently seen include central and spiral cords. Active and passive ROM 
testing during the intermediate disease will often reveal no limitations in patients with nodules, 
but as cords form patients will begin to lose extension of the involved joint.
5.3. Late phase
Late disease is defined by contraction of cords and the classic “bent finger” appearance of 
Dupuytren’s disease (Figure 2). Approximately 10% of Dupuytren’s disease patients will 
present during the late stage of the disease complaining of a permanent bent finger [12]. 
Contracture of the MCP joint often occurs before the PCP joint. Contractures often lead to dif-
ficulties in activates of daily living and patients will report difficulties with chores, washing, 
putting a hand in a pocket, and handshakes. Inspection and palpation will reveal a contracted, 
fibrotic cord. Both active and passive finger extension of the effected finger will likely be 
impaired, the extent of which is determined by severity of disease. Pain with ROM is rarely 
reported and if present should prompt further evaluation. The table top test was described in 
1982 by Hueston and is specific to a Dupuytren’s diagnosis and has been used to stage disease 
progression [50]. The test involves placing the patient’s hand on a tabletop with the palmar 
side down. The test is positive if the patient cannot flatten the hand against the table and is 
indicative of the late phase of the disease.
Figure 2. A patient with Dupuytren’s PIP joint contracture with a flexion contracture of approximately 100°.
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The degree of extension deficit is taken into account when staging Dupuytren’s disease. The 
adapted Tubiana staging system is the most common method of classifying the progression 
of Dupuytren’s disease (Table 1) [51, 52].
6. Diagnosis
Dupuytren’s disease is a clinical diagnoses based on a patient’s history and physical exam. 
Its hallmark features consist of an indolent, progressive course characterized by palmar skin 
changes, painless nodules, and fibrotic cords leading to flexion contractures of the digits. 
Patients presenting with later findings of the disease consisting of fibrotic cords and con-
tracted digits are more clearly diagnosed. Conversely, patients presenting with earlier fea-
tures of Dupuytren’s disease such as painless nodules may not be as easily distinguished 
from other diseases. Stenosing tenosynovitis, also known as a trigger finger, and soft tissue 
tumors may be mistaken for Dupuytren’s disease. Stenosing tenosynovitis can be differenti-
ated from Dupuytren’s by tenderness over the A1 pulley with symptomatic locking or trigger-
ing of the digit and often no ROM deficit. Soft tissue masses typically do not present with skin 
thickening and pitting as seen in Dupuytren’s disease. In addition, Dupuytren’s nodules are 
often fixed to the skin and palmar fascia. Early Dupuytren’s disease may be difficult to distin-
guish from diabetic cheiroarthropathy, however, involvement of multiple digits and a waxy 
appearance of the skin are clues to distinguish diabetic cheiroarthropathy. Other patholo-
gies that may present with some features similar to Dupuytren’s disease include: ulnar claw, 
rheumatoid arthritis, Volkmann’s contracture, and camptodactyly. Radiographs should be 
considered in patients presenting with a history of trauma to rule out a fracture or disloca-
tion. Further diagnostic imaging such as MRI may be considered in special cases to rule out 
suspicion of other disease processes, but is not required to diagnose Dupuytren’s disease. A 
thorough history and physical exam is key to accurately diagnosing Dupuytren’s disease.
7. Nonoperative treatment
Despite the recent advances in understanding the pathophysiology of Dupuytren’s disease 
the treatment options remain palliative and not curative. Non-operative treatment is recom-
mended in patients with isolated disease without contractures and in patients with mild 
contractures without significant interference with activities of daily living. Observation is a 
reasonable non-operative option for many patients with early disease and minimal symp-
toms. Studies have estimated about 50.8% of patients with palpable nodules will progress to 
developing cords after 8 years from diagnosis, and of these only 17% will develop contrac-
tures meeting criteria for surgical intervention [53].
Surgery is the mainstay treatment for Dupuytren’s contractures. However, non-operative 
interventions continue to be pursued as an alternative option to surgical intervention. Splinting 
and physical therapy have mostly been utilized as a post-operative intervention to prevent 
recurrence. Critics of splinting and physical therapy often express concern it may worsen 
the contracture if the contractile tissue is not first removed. In vitro studies have reported 
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mechanical loads increase TGF-beta expression and thus enhance fibroblast contraction [54]. 
Few clinical studies have investigated orthosis or therapy as a non-operative intervention. 
Larocerie-Salgado et al. reported patients with mild PIP joint contractures had an average 
improvement of 14.6° (SD 5.1°) after wearing a volar hand-based extension splint at night and 
utilizing hand exercises and massage [55]. Another study comparing tension and compression 
orthosis worn for 20 hours per day reported significant improvement in the total active exten-
sion (TAE) of a digit in both groups compared to baseline TAE [56]. Overall there is minimal 
evidence regarding therapy and orthosis usage. There may be some benefit in preventing 
progression of a contracture in an isolated digit, but the possible benefit may be minimal and 
outweighed by interference of the splint and necessity for prolonged periods of daily use.
Intralesional triamcinolone injections have also been proposed to deter the progression of 
Dupuytren’s disease. Steroid treatment in Dupuytren’s is linked to its effectiveness in reducing 
hypertrophic scars and keloids by degrading insoluble collagen. Ketchum and Donahue reported 
resolution of Dupuytren nodules in patients with mild disease (<15° joint contracture) after an 
average of three 60-120 mg triamcinolone injections spaced out over 6 weeks [57]. However, 
50% experienced recurrence of disease and either underwent further injections or surgery. Other 
studies have utilized triamcinolone in patients with nodules but without flexion contractures 
and have demonstrated better outcomes with only a 6% recurrence at 5 years [58]. The high 
recurrence rates and complications including skin atrophy, transient erythema, depigmentation 
and tendon rupture have minimized the use of steroid injections in Dupuytren’s disease [57, 58].
Non-operative treatment has recently expanded to include office-based procedures to pro-
vide patients with Dupuytren’s contractures an alternative to surgery or treat patients unable 
to tolerate surgery. Percutaneous needle fasciotomy and collagenase injections are two clinic 
procedures that have recently gained popularity. Zhao et al. reported these two minimally 
invasive techniques comprised 14% of all procedures for Dupuytren’s in 2007, but have more 
recently risen to 39% of all procedures [59].
7.1. Percutaneous needle fasciotomy
Percutaneous needle fasciotomy (PNF) utilizes a 25-gauge needle as a scalpel to incise the 
contracted cord at different levels while the digit is manually straightened. Prior to the proce-
dure the dermis is injected with a local anesthetic to reduce pain and is followed by range of 
motion (ROM) exercises aimed at preventing recurrence of the cord. As described by Eaton, 
needle fasciotomy has four requirements including a contracture caused by a palpable cord, 
redundant skin, and a cooperative patient [60]. The benefits of the procedure include a low 
complication rate, early return of motion, and avoidance of surgery. Zhou et al. reported a 
complication rate of 5.2% after fasciotomy compared with 24.3% in a group undergoing lim-
ited fasciectomy [61]. However, PNF had a higher rate of recurrence at long-term follow-up. 
Van Rijssen et al. have reported recurrence rates following PNF as high as 63% at 3 years and 
84.9% at 5-year follow-up [62]. Patients older than 75 years old with mild disease had the 
lowest rate of recurrence at 5 years. In general, PNF is a reasonable option for older patients 
who have developed a mild contracture due to a palpable cord and are well-informed of the 
recurrence risk but prefer a minimally invasive option.
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7.2. Collagenase injections
Collagenase injections were first approved for Dupuytren’s contractures in 2010 by the United 
States Food and Drug Administration and are currently approved for the treatment of two 
Dupuytren’s contracted joints in the same hand. Collagenase injections deliver an enzyme iso-
lated from Clostridium histolyticum which is responsible for lysing the collagen in a contracted 
cord. After injection, the patient returns within 1–3 days for manipulation to straighten the 
digit. Hurst et al. reported good results following up to 3 injections with 64% of patients expe-
riencing 0–5° of full flexion with no recurrence 90 days after treatment [63]. Common adverse 
events of collagenase included swelling, pain, bruising, tenderness, and pruritis. Complications 
related to tendon ruptures, skin atrophy, and complex regional pain syndrome (CRPS) are rare 
and have been reported in less 1% of patients [63, 64]. Recurrence rates following collagenase 
have been closely studied as well. Van beek et al. reported 2-year recurrence rates (>20-degree 
worsening) following one or more injections were 28.2 and 62.1% for MCP and PIP joints, 
respectively [65]. Peimer et al. reported 47% of successfully treated patients experience recur-
rence (>20° worsening) within 5-years following collagenase injections with PIP joints having 
a higher degree of recurrence at 66 versus 39% among MCP joints [64]. Collagenase injections 
provide a good treatment option for patients with a palpable cord causing a contracture.
8. Operative treatment
Operative treatment of Dupuytren’s disease is offered in patient with contractures of >30° at 
the MCP joint and any functionally bothersome PIP contracture. The goal of surgical treat-
ment is to return full extension of the involved digits via various surgical techniques involv-
ing either incising or excising the diseased fascia. Dupuytren originally described an open 
palmar fasciotomy technique in 1831 and this was later popularized in 1964 by McCash et al. 
as the open-palm technique [6, 66]. The open-palm technique involved a transverse incision 
across the distal palmar crease followed by incising any Dupuytren cords. Multiple surgi-
cal methods have since been described and include open fasciotomy, segmental fasciectomy, 
limited fasciectomy, and dermofasciectomy. These techniques range from being minimally 
invasive to radical excision of the diseased tissue. It is important to consider the severity of 
contractures, extent of correction, and risk factors for recurrence in addition to protecting soft 
tissues when choosing the optimal surgical treatment. Surgery is ultimately an elective form 
of treatment and should prompt a conversation with patients regarding the risk and benefits 
of surgery as well as their functional goals.
8.1. Soft tissues
Proper handling of soft tissue is a key principle of surgical treatment of Dupuytren’s con-
tractures. Adequate exposure of the cord must be balanced with protecting the neurovascular 
bundles, providing adequate wound coverage, limiting the risk of skin necrosis, and avoid-
ing secondary contractures from longitudinal scarring. Multiple skin incisions have been 
described to address these issues and include: transverse incisions in the palm and digit, a 
Dupuytren’s Disease
http://dx.doi.org/10.5772/intechopen.72759
69
Bruner incision, a Bruner incision with V-Y advancement flaps, curved incisions, and a lon-
gitudinal incision closed with z-plasties (Figure 3). Midline incisions provide the benefit of 
potentially avoiding the neurovascular bundles, however, Dupuytren’s disease distorts regu-
lar anatomy and can tether the cord toward the midline. Curved or zig-zag incisions help avoid 
secondary contractures from longitudinal scars. Despite the many variations in incisions, the 
Bruner incision seems to be the most commonly used.
Skin closure is another important aspect of treating Dupuytren’s disease. The open-palm 
technique described by McCash left the skin incisions open to decrease hematoma formation 
and allowed for secondary healing with good results [66]. Today, most incisions are closed 
primarily, however, increased skin tension after closure has been correlated with elevated 
recurrence rate (Figure 4). Citron and Hearnden randomized patients undergoing fascioto-
mies and reported a 50% recurrence rate in the group with transverse incisions closed primar-
ily compared with a 15% rate in patients with longitudinal incisions with a z-plasty closure 
[67]. Another study compared Bruner’s incision with direct closure to a longitudinal incision 
with a z-plasty closure for fasciectomy and reported no difference between the two methods 
[68]. Special attention should be given to skin tension during closure and a transpositional 
flap such as a z-plasty should be utilized if needed.
8.2. Open fasciotomy
Open fasciotomy includes a variety of surgical techniques for treating Dupuytren’s contractures 
by incising the contracted cord without removing the diseased fascia. Many of the modern fas-
ciotomy techniques are modifications of the methods originally described by Dupuytren and 
Figure 3. The figure outlines types of incisions and closures options for treating Dupuytren’s disease. Thumb: longitudinal 
incision with z-plasty closure. Index finger: Brunner incision. Middle finger: curvilinear incision. Index finger: V-Y incision. 
Small finger: transverse incisions utilized in the McCash open palm technique.
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McCash et al. [6, 66]. Various types of incisions may be utilized to access the cord, but once the 
cord is visualized and incised, the digit is extended until straight. In some cases, additional 
incisions may be required at different levels along the cord in order to fully extend the digit. 
Unlike PNF, an open fasciotomy procedure provides the benefit of direct visualization to pro-
tect neurovascular structures and can often be accomplished through small incisions. In addi-
tion, it minimizes the potential morbidity sometimes seen in other techniques which excise the 
diseased fascia. Still, excision techniques are often preferred over an open fasciotomy for their 
ability to remove the diseased fascia which may aid in preventing regrowth of the cord and 
recurrence. This may be particularly true in patients with severe contractures. Stewart et al. 
retrospectively reviewed a series of patients who had open fasciotomies and reported a reop-
eration rate of 13.2% at 46 months with patients who initially required three level fasciotomies 
having worse recurrence [69]. Another study assessed 16 patients with Tubiana stage III and IV 
contractures and reported a higher recurrence rate of 37.5% at 5–8 year follow-up [70].
8.3. Fasciectomy
Fasciectomy is the most common surgical treatment for Dupuytren’s contractures. The tech-
nique is based on the concept that the remaining diseased fascia may proliferate and lead to 
recurrence. Multiple methods of fasciectomies have been described and range from a segmen-
tal fasciectomy, where a portion of the fascial cord is removed, to a radical fasciectomy where 
skin and diseased fascia are excised. A segmental fasciectomy is usually completed through 
small incisions where segments of the cord are excised until the finger straightens. No attempt 
Figure 4. A post-operative image of a patient after a limited fasciectomy for a Dupuytren’s contracture of the small and 
ring finger. The Brunner’s incision was closed primarily with nylon sutures.
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is made to removal the complete cord. The most widely used technique is a limited fasciectomy 
and is considered the gold standard in the operative treatment of Dupuytren’s contractures 
(Figure 5). The technique involves carefully exposing the diseased fascia from its proximal to 
distal end and excising it from the surrounding soft tissue (Figure 6). It differs from a radical 
fasciectomy by removing only the diseased fascia and leaving normal fascia, subcutaneous 
tissue, and the dermis intact. Radical fasciectomy advocated by McIndie and Beare involved 
extensive removal of nearby tissue and skin and required a skin graft [71]. However, the 
technique largely fell out of favor due to a higher complication rate without a reduction in 
recurrence. A dermatofasciectomy is similar to a limited fasciectomy but involves excising 
the overlying skin and often requires a skin graft for coverage. Advocates of this technique 
report disease-forming cells may be left in the overlying soft tissue leading to recurrence and 
selectively use it in patients at higher risk for recurrence. Despite the variety of techniques, 
fasciectomies require meticulous dissection to avoid injuring neurovascular bundles which 
may be displaced by a contracted cord. In addition, maintaining hemostasis is important to 
prevent hematoma formation which can compromise healing. Overall, fasciectomies offer the 
benefit of removing more diseased fascia but are accompanied by increased morbidity related 
to a more extensive exposure.
8.4. Post-operative protocol
Most surgeons utilize some form of rehabilitation to prevent further contractures and main-
tain ROM. After surgery, patients are typically immobilized in an extension-based splint for 
2–3 days. Wounds are closely monitored following surgery to ensure adequate healing and to 
identify any barriers to healing such as infection, hematoma, or skin necrosis. Patients are often 
referred to a hand therapist within the first week of surgery for wound care, scar management, 
range of motion exercises, and splinting techniques to prevent contracture formation. A variety 
of splinting protocols and types of orthoses have been described. In general, protocols may 
involve static or dynamic splinting and be utilized at different periods of the day. Despite the 
widespread use of post-operative splinting, studies have found no strong evidence they are 
effecting in preventing loss of extension or recurrence. Collis et al. randomized patients to night 
Figure 5. An intraoperative image of a patient undergoing a limited fasciectomy for a Dupuytren’s contracture of the small 
finger. A Brunner’s incision was utilized to exposed the disease tissue. The Dupuytren’s cord is being elevated by the forceps.
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time extension orthoses and hand therapy or hand therapy alone and reported no differences 
between the two groups in terms of active ROM or hand function [72]. A similar study found 
night time splinting offered no benefit in terms of ROM and function at 1 year after surgery and 
recommended splinting should only be utilized when extension deficits occur [73]. Overall, less 
invasive procedures allow for earlier rehabilitation and a shorter recovery period. In addition, 
wound healing often dictates how fast a patient can progress following surgery. A segmental 
aponeuroectomy may involve a 2–3 week recovery period whereas a fasciectomy may involve 
a much longer recovery period.
9. Patient outcomes
Overall, surgery is an effective method of treating Dupuytren’s contractures and improv-
ing patients’ hand function. In a survey of over 1100 patients who underwent surgical treat-
ment 75% reported almost full or full correction of their contracture [74]. Zyluk et al. reported 
patients had significantly improved hand function as measured by the Disabilities of the Arm, 
Shoulder, and Hand (DASH) questionnaire after undergoing a subtotal fasciectomy [75]. In 
Figure 6. An intraoperative image of a patient undergoing a limited fasciectomy for a Dupuytren’s contracture of the 
ring finger. (A) A Brunner’s incision was utilized to exposed the disease tissue. The longitudinal band of the palmar 
aponeurosis is being elevated. (B) The diseased fascia was meticulously elevated from proximal to distal. (C) The diseased 
fascia after removal from the digit.
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addition, patient’s experienced a significant improvement in the total loss of extension from 
an average of 80 to 10°. Another study prospectively evaluated 90 patients undergoing a fas-
ciectomy for a 60-degree or more deficit in total active extension and reported 81% patient 
satisfaction with function, 87% reaching functional ROM, and significantly improved DASH 
scores at 1 year follow up [76].
Further analysis of surgical treatment has lead authors to identify certain characteristic asso-
ciated with better outcomes. Patients with MCP contractures are more likely to achieve full 
intra-operative correction (Donaldson). However, correction of PIP contractures has a stron-
ger correlation to improved hand function when compared with correction of the MCP joint 
[77]. Surgical treatment has focused on PIP contractures to maximize intra-operative correc-
tion and improve functional outcomes. Surgeons have tried releasing the PIP capsule with 
a fasciectomy to improve PIP correction, but there is no strong data to support whether it is 
effective [78]. Zyluk et al. reported younger patients had a significantly greater functional 
improvement after surgery as measured by the DASH score [75]. Studies have also cited the 
extent of preoperative deformity, incomplete correction, and multiple involved digits as fac-
tors affecting post-operative functional outcomes [75, 78–80].
Despite multiple studies reporting good outcomes after surgery, there are limited random-
ized studies comparing outcomes after different operative techniques. Ullah et al. found 
no difference in ROM or recurrence in 79 patients randomized to either direct closure with 
z-plasty or firebreak skin grafting after a fasciectomy, however, patients with skin grafting 
had an increased incidence of hypoesthesia [81]. Van Rijssen et al. randomized patients 
to percutaneous needle fasciotomy and limited fasciectomy and reported the PNF group 
was significantly higher recurrence rate (76.8 vs. 20.9%, p < 0.001) and lower VAS satisfac-
tion scores (6.2 vs. 8.3, p < 0.001) [62]. Further prospective, randomized studies reporting 
functional outcomes, complications, and recurrence rates are necessary to recommend any 
surgical procedure.
10. Recurrence
Recurrence of a Dupuytren’s contracture is a common event even after successful initial treat-
ment. A systematic review analyzed 51 studies and reported recurrence rates ranged from 0 to 
71% [82]. Furthermore, recurrence rates are difficult to assess as there is considerable variation 
in the criteria used to define recurrence. Some authors report the presence of any diseased 
tissue after treatment while others include only contractures necessitating re-operation. More 
recently, studies have tended to define recurrence as a 20–30° loss of extension in a success-
fully treated digit. A recent randomized study defined recurrence as a 20° reduction of total 
passive extension in a successfully treated digit and reported a 20.9% 5-year recurrence rate 
after limited fasciectomy [62].
Multiple studies have focused on identifying factors which may predispose patients to recur-
rence. The dramatic variability of recurrence rates may be due to the heterogeneity of the 
presentation of Dupuytren’s itself, as many patients may have more aggressive biology associ-
ated with “Dupuytren’s diathesis”, whereas others may have more mild disease. Dupuytren 
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diathesis is a term coined by Hueston describing certain characteristics related to severe dis-
ease and increased recurrence [83]. Hindocha modified the criteria to include the following 
features within a Northern European population: male sex, <50 years old, bilateral disease, 
affected parent or sibling, and presence of Garrod’s nodes and reported patients with all 5 
features had a recurrence rate of 71% [84]. However, other studies have failed to demonstrate a 
significant correlation with recurrence among all 5 diathesis criteria. Van Rijssen reported only 
older age was found to delay recurrence after PNF and limited fasciectomy [62]. PIP joint con-
tractures have an elevated recurrence rate after surgery compared to the MCP joint. Donaldson 
et al. reported 34.2% of fully corrected PIP joints experienced at least some loss of correction 
compared with 12.2% of MCP joints [80]. Patients with severe preoperative PIP contractures 
greater than 60°, incomplete correction, and poor post-operative compliance had significantly 
worse recurrence [78].
Surgical management of recurrent disease is challenging as anatomic landmarks and tis-
sue plans become difficult to distinguish. There is currently limited data regarding the 
preferred surgical treatment. Roush and Stern compared dermatofasciectomy with a skin 
graft, interphalangeal joint arthrodesis, and fasciectomy with local flaps among 19 patients 
with recurrence after a prior surgery [85]. The fasciectomy cohort was the only group to 
significantly maintain total active motion at final follow-up, but all three groups had simi-
lar patient reported outcomes. It is important patients are aware of the risk of recurrence 
prior to their initial surgery and personal factors which may increase their likelihood of 
recurrence.
11. Complications
Despite good outcomes after surgical treatment of Dupuytren’s contractures surgery is 
not without complications. A 20 year systematic review of complications by Denkler et al. 
reported an average major complication risk of 15% with complication rates ranging from 3.6 
to 39.1% [86]. Specific complications after limited fasciectomy included the following: wound 
healing problems, 22.9%; flare reaction, 9.9%; complex region pain syndrome, 5.5%; nerve 
injury, 3.4%; infection, 2.4%; hematoma, 2.1%; and digit artery injury, 2%. Severe complica-
tions include tendon rupture or loss of the digit but are extremely rare. Patients with severe 
flexion contractures are more at risk of experiencing a complication [87]. Smoking and dia-
betes, however, has not been identified as an increased risk factor for wound healing prob-
lems after surgery [88]. Patients undergoing revision surgery for recurrence are most at risk 
for complications, especially neurovascular injuries due to scar tissue and loss of anatomic 
landmarks. Neurovascular injuries have been reported as high as 10 times more common in 
revision surgeries for recurrence [86].
12. Conclusion
Dupuytren’s disease is a unique fibroproliferative disorder of palmar fascia likely resulting 
from a complex interplay of genetic and environmental factors. Despite extensive research, 
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its etiology remains unclear and treatment methods remain palliative. Observation is an 
acceptable form of treatment for mild disease and patients with low functional status. 
Collagenase injections and percutaneous fasciectomy are becoming more common as an 
initial treatment method for patients with isolated disease and a palpable cord. Surgical 
indications typically include a flexion contracture of >30° at the MCP joint and 10–15° at 
the PIP joint but are also influenced by patients’ functional goals. Limited fasciectomy is 
the preferred method of surgical treatment by most surgeons. However, there is insuffi-
cient high quality evidence comparing different methods of treatment. In general, start-
ing with a less invasive treatment is a reasonable approach; the recurrence rate may be 
higher, but patients will benefit from a quicker rehabilitation and a lower complication 
rate. Limited fasciectomy can then be reserved for more severe disease, initial treatment 
failures, or recurrence. PIP contractures, however, may benefit from earlier intervention 
due to their impact on function, increased likelihood of incomplete correction, and higher 
recurrence rate. Overall, surgery is an effective treatment for Dupuytren’s contractures but 
complications can occur especially related to wound healing, and many patients experience 
recurrence. Further research is still needed to compare treatment modalities and determine 
appropriate indications.
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